News Conference News AHA 2025 Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids Michael O'Riordan November 10, 2025
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2023 Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH Caitlin E. Cox November 12, 2023
News Conference News AHA 2023 RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1 Caitlin E. Cox November 11, 2023
News Conference News AHA 2022 SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint Todd Neale November 09, 2022
News Conference News AHA 2020 Rilonacept Prevents Recurrent Pericarditis: RHAPSODY Shelley Wood November 17, 2020
News Conference News AHA 2018 Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study Shelley Wood November 11, 2018
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016
News Conference News AHA 2012 AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community Jason Kahn November 11, 2012